Cellectar Biosciences and Evestia Clinical, a leading independent global specialist Contract Research Organization (CRO), have partnered, Cellectar announced recently.

According to a release, Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for the treatment of triple-negative breast cancer (TNBC).

“ARG has been a trusted CRO partner for years, and we are pleased to continue to work with the expanded team at Evestia Clinical, confident that their combined expertise and tailored approach will be instrumental in contributing to the success of this important clinical trial,” Cellectar Biosciences Chief Operating Officer Jarrod Longcor said in a statement. “We have unwavering confidence in CLR 125, and initiation of the Phase 1b trial in TNBC will represent a significant milestone toward bringing a new treatment option to patients.”

The biotech company also selected a Mayo Clinic Network site as a treatment center for the Phase 1b clinical trial of CLR 125 in TNBC.